Optimizing Cannabinoid
Delivery Technologies
Safe. Effective. Convenient.
Optimizing Cannabinoid
Delivery Technologies
Safe. Effective. Convenient.
VISION
Same Plant, Safer Consumption
The world needs safer, more effective, more convenient methods for the intake of cannabinoids.
We believe technology is the answer. We’re laser-focused on optimizing the delivery of cannabinoids through novel devices and formulations.
And our team has the expertise to back up our vision — from engineering and chemistry to regulatory strategy, clinical affairs, global launch, and distribution strategy.
VISION
Same Plant, Safer Consumption
The world needs safer, more effective, more convenient methods for the intake of cannabinoids.
We believe technology is the answer. We’re laser-focused on optimizing the delivery of cannabinoids through novel devices and formulations.
And our team has the expertise to back up our vision — from engineering and chemistry to regulatory strategy, clinical affairs, global launch, and distribution strategy.
Abhi obtained his doctorate in neuropharmacology from the University of Toronto, during which time he conducted translational research evaluating novel cannabinoid therapeutics and medical devices from animal models to human clinical trials. He has extensive experience designing clinical trials supported by the US National Institute of Health and the Canadian Institutes for Health Research, as well as to obtain global regulatory approvals of medical devices and biopharmaceutical products. Most recently, he led the clinical and regulatory affairs team of a medical device consulting firm and was responsible for successful regulatory submissions for a variety of diagnostic and therapeutic products.
Michael Klein has been successfully developing innovative medical technologies for ten years by working at the interface of engineering and the life sciences. Michael spent six years at Thornhill Medical building novel respiratory devices to improve mechanical ventilation, inhalational anesthesia delivery, and non-invasive hemodynamic monitoring. His developments led to multiple patent applications and commercialization opportunities for Thornhill Medical. Michael continued his career as Assistant Director of Research and Development at Xagenic, where he designed new assays and biosensors for a point-of-care molecular diagnostic platform. As a consultant, Michael applied his unique combination of design, research, and strategic thinking skills to lead projects in a variety of fields such as molecular diagnostics, respirology, cardiology, and gastroenterology, helping numerous companies successfully navigate the path to market. Michael holds a Bachelor of Applied Science degree from the University of Waterloo and a Master of Science degree with a research focus in respiratory physiology from the University of Toronto.
Joel is a medical technology development expert with over 15 years of experience developing novel medical technologies, particularly respiratory devices. His experience includes technical development, regulatory approvals and the design and execution of first-in-man and pivotal clinical trials. He has brought more than a dozen innovative healthcare products from concept through to commercialization, and has held executive positions as CEO, COO, VP Product Development, and VP Clinical and Regulatory Affairs at several medical technology companies.
Vijay Sappani is a successful diversified cannabis entrepreneur and angel investor in several Cannabis start-ups. He is currently Founder and CEO of Ela Capital Inc, a boutique investment and advisory services firm focused on cannabis, medical devices and healthcare sector. He is founder at High 12 brands, a premium Cannabis CPG company and founder and former Chief Strategy Officer of TerrAscend, one of the largest publicly traded Canadian Cannabis company. He is also board member of Canadians for Fair Access to Medical Marijuana (CFAMM) and has been a speaker and panelists in many conferences.
Vijay has over 15 years of multinational experience in pharmaceuticals, medical devices, government and security. He has held senior positions with Natco Pharma, Mylan and Biovail. He also served as Senior Special Assistant to the Ontario Minister of Health and Long-Term Care and was a member of the board for the ministry’s Pharmacy Council. Currently he serves on the board of the MacDonald Laurier Institute, CDG Canada rare disease group and has previously served on the boards of over a dozen community and national organizations.
Vijay holds a Bachelor of Pharmacy from and a post-graduate in marketing management.
FOUNDERS
Experts in Our Fields
Our founders have successfully commercialized dozens of innovative medical and wellness products, contributing to the growth of $1B+ companies in the process. These companies have improved consumers quality of life while generating transformative revenue.
FOUNDERS
Experts in Our Fields
Our founders have successfully commercialized dozens of innovative medical and wellness products, contributing to the growth of $1B+ companies in the process. These companies have improved consumers quality of life while generating transformative revenue.
Abhi obtained his doctorate in neuropharmacology from the University of Toronto, during which time he conducted translational research evaluating novel cannabinoid therapeutics and medical devices from animal models to human clinical trials. He has extensive experience designing clinical trials supported by the US National Institute of Health and the Canadian Institutes for Health Research, as well as to obtain global regulatory approvals of medical devices and biopharmaceutical products. Most recently, he led the clinical and regulatory affairs team of a medical device consulting firm and was responsible for successful regulatory submissions for a variety of diagnostic and therapeutic products.
Joel is a medical technology development expert with over 15 years of experience developing novel medical technologies, particularly respiratory devices. His experience includes technical development, regulatory approvals and the design and execution of first-in-man and pivotal clinical trials. He has brought more than a dozen innovative healthcare products from concept through to commercialization, and has held executive positions as CEO, COO, VP Product Development, and VP Clinical and Regulatory Affairs at several medical technology companies.
Vijay Sappani is a successful diversified cannabis entrepreneur and angel investor in several Cannabis start-ups. He is currently Founder and CEO of Ela Capital Inc, a boutique investment and advisory services firm focused on cannabis, medical devices and healthcare sector. He is founder at High 12 brands, a premium Cannabis CPG company and founder and former Chief Strategy Officer of TerrAscend, one of the largest publicly traded Canadian Cannabis company. He is also board member of Canadians for Fair Access to Medical Marijuana (CFAMM) and has been a speaker and panelists in many conferences.
Vijay has over 15 years of multinational experience in pharmaceuticals, medical devices, government and security. He has held senior positions with Natco Pharma, Mylan and Biovail. He also served as Senior Special Assistant to the Ontario Minister of Health and Long-Term Care and was a member of the board for the ministry’s Pharmacy Council. Currently he serves on the board of the MacDonald Laurier Institute, CDG Canada rare disease group and has previously served on the boards of over a dozen community and national organizations.
Vijay holds a Bachelor of Pharmacy from and a post-graduate in marketing management.
MEDICAL
Putting
Patients First
Smoking is not a medical delivery method, yet patients have accepted it as the fastest and simplest method for them to medicate with cannabinoids. We aim to change the game with truly medical alternatives designed for health and quality of life.
Healthcare professionals expect 21st century drug delivery and dosing technologies. Our delivery systems are built with their input and based on standard-of-care medical practice.
Whether it be in hospitals or at home, we believe patients and their caregivers should be able to safely and effectively administer cannabinoid medications in a fashion that is quick and simple.
MEDICAL
Putting
Patients First
Smoking is not a medical delivery method, yet patients have accepted it as the fastest and simplest method for them to medicate with cannabinoids. We aim to change the game with truly medical alternatives designed for health and quality of life.
Healthcare professionals expect 21st century drug delivery and dosing technologies. Our delivery systems are built with their input and based on standard-of-care medical practice.
Whether it be in hospitals or at home, we believe patients and their caregivers should be able to safely and effectively administer cannabinoid medications in a fashion that is quick and simple.
WELLNESS
Legalization Doesn't Have To Mean More Smoke
Many of us would like to use cannabinoids as a holistic part of a healthy lifestyle. But smoke is dangerous, and edibles can be a truly scary step into the deep end.
We’re developing novel delivery alternatives — no smoke, no smell, no taste — that provide relief from symptoms as quickly as smoking does.
Apart from cannabinoids, our formulations keep the terpenes and other holistic phytochemicals extracted from the plant. Same plant, safer consumption.
WELLNESS
Legalization Doesn't Have To Mean More Smoke
Many of us would like to use cannabinoids as a holistic part of a healthy lifestyle. But smoke is dangerous, and edibles can be a truly scary step into the deep end.
We’re developing novel delivery alternatives — no smoke, no smell, no taste — that provide relief from symptoms as quickly as smoking does.
Apart from cannabinoids, our formulations keep the terpenes and other holistic phytochemicals extracted from the plant. Same plant, safer consumption.